ERBB2 and breast cancer: The presence of genetic aberrations such as PIK3CA mutations, PTEN loss and HER2 amplification are frequent in breast cancer and whilst data suggest they could predict for greater sensitivity to PI3K pathway inhibition, not all sensitivity to PI3K inhibitors can be explained by these markers [2], [3], [4].